DP
APVO icon

Diadema Partners’s Aptevo Therapeutics APVO Stock Holding History

Diadema Partners’s Portfolio APVO Stock Details APVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-11
Closed -$17.5K – 110
2024
Q4 		$17.5K Buy
+11
New +$31.6K 0.01% 104

Other funds holding APVO

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.25% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Diadema Partners's APVO Position: Q1 2025 in Review

Diadema Partners sold out of Aptevo Therapeutics (APVO) in Q1 2025, closing a stake of 11 shares — an estimated $17.5K sold.

Diadema Partners first reported a position in APVO in Q4 2024 and held it in 1 quarter. The position peaked at $17.5K in Q4 2024. 5 funds tracked by Wall St. Rank hold APVO as of Q1 2025.

  • Diadema Partners reported no remaining Aptevo Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Diadema Partners sold 11 Aptevo Therapeutics shares in Q1 2025, an estimated $17.5K.
  • Diadema Partners first reported a position in Aptevo Therapeutics in Q4 2024 and held it in 1 quarter.
  • Diadema Partners's Aptevo Therapeutics position peaked at $17.5K in Q4 2024.
  • 5 funds tracked by Wall St. Rank held Aptevo Therapeutics as of Q1 2025.

Based on Diadema Partners's 13F filing for Q1 2025, filed 15 May 2025.